TY - JOUR
T1 - Current Immune-Related Molecular Approach in Combating Nasopharyngeal Cancer
AU - Argadikoesoema, Soehartati
AU - Adham, Marlinda
AU - Kodrat, Henry
AU - Tobing, Demak Lumban
AU - Haryoga, I. Made
AU - Dwiyono, Agustinus Gatot
AU - Kristian, Yoseph Adi
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Nasopharyngeal cancer is a cancer closely related to Epstein-Barr virus (EBV) infection. EBV protein has been shown to be related to various oncogenic development. Suppression of tumor suppressor genes, upregulating molecules to prevent immune attack, downregulating pro-apoptotic proteins, and stimulating local immune suppressive environment are among some roles that EBV proteins can exert on host cells. All those factors combined together with underlying genetic susceptibility of host cells further increase the chance of nasopharyngeal cancer development. Approach targeting those carcinogenesis pathways has been tested with marginal benefit. A newer approach boosting immune cells to increase recognition of tumor antigen and promoting cytotoxic T cell attack has shown promising clinical benefit. Further combination of those immunotherapies with other modality, in particular radiotherapy, has resulted in amplification of cancer killing.
AB - Nasopharyngeal cancer is a cancer closely related to Epstein-Barr virus (EBV) infection. EBV protein has been shown to be related to various oncogenic development. Suppression of tumor suppressor genes, upregulating molecules to prevent immune attack, downregulating pro-apoptotic proteins, and stimulating local immune suppressive environment are among some roles that EBV proteins can exert on host cells. All those factors combined together with underlying genetic susceptibility of host cells further increase the chance of nasopharyngeal cancer development. Approach targeting those carcinogenesis pathways has been tested with marginal benefit. A newer approach boosting immune cells to increase recognition of tumor antigen and promoting cytotoxic T cell attack has shown promising clinical benefit. Further combination of those immunotherapies with other modality, in particular radiotherapy, has resulted in amplification of cancer killing.
UR - https://www.wjon.org/index.php/WJON/article/view/1214
U2 - 10.14740/wjon1214
DO - 10.14740/wjon1214
M3 - Article
VL - 10
SP - 157
EP - 161
JO - World Journal of Oncology
JF - World Journal of Oncology
SN - 1920-4531
IS - 4-5
ER -